ISSN |
1948-5204 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Retrospective Study |
Article Title |
Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Lauren Midthun, Sungjin Kim, Andrew Hendifar, Arsen Osipov, Samuel J Klempner, Joseph Chao, May Cho, Michelle Guan, Veronica R Placencio-Hickok, Alexandra Gangi, Miguel Burch, De-Chen Lin, Kevin Waters, Katelyn Atkins, Mitchell Kamrava and Jun Gong |
Funding Agency and Grant Number |
|
Corresponding Author |
Jun Gong, MD, Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, United States. jun.gong@cshs.org |
Key Words |
Esophageal cancer; Metastatic; Chemotherapy; Predictors; Survival |
Core Tip |
We evaluated a large cancer database of metastatic esophageal cancer cases to identify predictors of receipt to chemotherapy and survival. We confirmed that although palliative, receipt of chemotherapy in metastatic esophageal cancer conferred an overall survival (OS) benefit over no chemotherapy. However, the benefit of this OS benefit with chemotherapy is time-dependent and favors early initiation. Furthermore, several socioeconomic and clinicopathologic factors were predictive for receipt of chemotherapy and OS in this cohort. |
Publish Date |
2022-02-10 14:26 |
Citation |
Midthun L, Kim S, Hendifar A, Osipov A, Klempner SJ, Chao J, Cho M, Guan M, Placencio-Hickok VR, Gangi A, Burch M, Lin DC, Waters K, Atkins K, Kamrava M, Gong J. Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. World J Gastrointest Oncol 2022; 14(2): 511-524 |
URL |
https://www.wjgnet.com/1948-5204/full/v14/i2/511.htm |
DOI |
https://dx.doi.org/10.4251/wjgo.v14.i2.511 |